Wang Hanzhi, Jiang Linxiang, Gao Bo, Dong Minyue
Women's Hospital, School of Medicine, Zhejiang University, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China; Key Laboratory of Reproductive Genetics, Ministry of Education, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China; Key Laboratory of Women's Reproductive Health of Zhejiang Province, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China.
Women's Hospital, School of Medicine, Zhejiang University, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China; Key Laboratory of Reproductive Genetics, Ministry of Education, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China; Key Laboratory of Women's Reproductive Health of Zhejiang Province, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China.
Clin Chim Acta. 2016 Apr 1;455:60-3. doi: 10.1016/j.cca.2016.01.030. Epub 2016 Jan 29.
Placental Semaphorin 3B (SEMA 3B) expression has been reported changed in preeclampsia and its possible involvement of in the disease proposed. We clarified the alterations of maternal SEMA 3B level in women suffering preeclampsia and pregnant women at gestational weeks of 16-20 before the onset of preeclampsia.
Serum SEMA 3B concentration was measured with ELISA in preeclamptic women (preeclampsia) and normotensive women (control) in 3rd trimester, and also in pregnant women at gestational weeks of 16-20 who developed preeclampsia or had favorable pregnant outcome.
Serum SEMA 3B level was significantly increased in preeclampsia compared with control (P<0.001). There was a significant difference in serum SEMA 3B between mild and severe preeclampsia (P=0.04). Women with severe preeclampsia had significant serum SEMA 3B than women with mild preeclampsia. At gestational weeks of 16-20, serum SEMA 3B was significantly higher in women who developed preeclampsia than women who had normal pregnant outcome (P<0.001).
Maternal SEMA 3B level increased in preeclampsia before the onset of manifestations, indicating that SEMA 3B plays a role in the pathogenesis of preeclampsia.
已有报道称子痫前期患者胎盘信号素3B（SEMA 3B）表达发生改变，并提出其可能参与该疾病的发生发展。我们明确了子痫前期患者及子痫前期发病前孕16 - 20周孕妇母体SEMA 3B水平的变化情况。
采用酶联免疫吸附测定法（ELISA）检测子痫前期患者（子痫前期组）和血压正常孕妇（对照组）孕晚期血清SEMA 3B浓度，同时检测孕16 - 20周发生子痫前期或妊娠结局良好的孕妇血清SEMA 3B浓度。
与对照组相比，子痫前期组血清SEMA 3B水平显著升高（P<0.001）。轻度子痫前期与重度子痫前期患者血清SEMA 3B水平存在显著差异（P = 0.04）。重度子痫前期患者血清SEMA 3B水平显著高于轻度子痫前期患者。孕16 - 20周时，发生子痫前期的孕妇血清SEMA 3B水平显著高于妊娠结局正常的孕妇（P<0.001）。
子痫前期患者在出现临床表现之前母体SEMA 3B水平升高，表明SEMA 3B在子痫前期发病机制中起作用。
